Many vaccines require cold chain storage and distribution, limiting their accessibility in resource-poor regions. Dry powder formulations offer a promising solution by eliminating the need for refrigeration. This technology can significantly improve global health, especially in low-income countries heavily burdened by infectious diseases like respiratory infections, malaria, and diarrheal diseases. By making vaccines more accessible, we can effectively combat these diseases and reduce their global impact.
In the webinar is presented the case study between AAHI and Lonza who have collaborated to develop a dry powder inhalable vaccine for tuberculosis. Using spray drying technology, they produced intranasal dry powder formulations combining the ID93 antigen and GLA-SE adjuvant. The team also assessed the physical properties of the powder and its performance when delivered through intranasal dry powder inhalers. You can read the entire whitepaper to learn more.